Clinical Trial Detail

NCT ID NCT02964078
Title Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute

kidney cancer


Aldesleukin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.